Can we prove value for therapies that prevent future harm – not just treat it?

Antimicrobial resistance posed complex long-term challenges with limited investment incentives and hard-to-measure benefits.

A novel framework and evaluative tools were developed combining population models, policy levers, and long-term outcome projections to quantify societal and payer value.